IDH1 and neoplasm: It has been shown that 80% of IDH mutations are enriched in C5 (Thorsson et al., 2018), while IDH mutations can lead to a decrease in tumor-associated immune cells and better prognosis by reducing leukocyte chemotaxis (Venteicher et al., 2017), which is consistent with the Low-CCNScore group.